The Food and Drug Administration has approved two drugs designed to slow Alzheimers progression by targeting amyloid plaques. The first Biogens Aduhelm was embroiled in controversy amid questions about how much it benefits patients. The second a drug called Leqembi developed by Eisai and Biogen may prove more successful after initial pushback from insurers before its full approval in July . The data supporting it are clearer in showing a benefit to treatment